Article de revue
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo
The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z). The researchers aimed to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z in Malian and US adults, and assess the effect of boosting of Malians with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other filovirus antigens (MVA-BN-Filo).
Full title: "Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial".
Auteurs
- Milagritos D. Tapia
- Samba O. Sow
- Kirsten E. Lyke
- Fadima Cheick Haidara
- Fatoumata Diallo
- Moussa Doumbia
- Awa Traore
- Flanon Coulibaly
- Mamoudou Kodio
- Uma Onwuchekwa
- Marcelo B. Sztein
- Rezwanul Wahid
- James D. Campbell
- Marie-Paule Kieny
- Vasee Moorthy
- Egeruan B. Imoukhuede
- Tommy Rampling
- Francois Roman
- Iris De Ryck
- Abbie R. Bellamy
- Len Dally
- Olivier Tshiani Mbaya
- Aurélie Ploquin
- Yan Zhou
- Daphne A. Stanley
- Robert Bailer
- Richard A. Koup
- Mario Roederer
- Julie Ledgerwood
- Adrian V. S. Hill
- W. Ripley Ballou
- Nancy Sullivan
- Barney Graham
- Myron M. Levine
Langues
- Anglais
Année de publication
2015
Journal
The Lancet Infectious Diseases
Volume
1
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Ebola
Pays
- Tchad
- Mali
- États-Unis
Régions de l'OMS
- Région africaine
- Région des Amériques
